Ipratropium Bromide

IPRATROPIUM BROMIDE — ipratropium bromide solution
Aurobindo Pharma Limited


The active ingredient in Ipratropium Bromide Inhalation Solution is ipratropium bromide monohydrate, USP. It is an anticholinergic bronchodilator chemically described as 8-azoniabicyclo[3.2.1]-octane,3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-, bromide, monohydrate (endo, syn)-,(±)-; a synthetic quaternary ammonium compound, chemically related to atropine.

Ipratropium Bromide Monohydrate Chemical Structure
(click image for full-size original)

Ipratropium bromide USP is a white to off-white crystalline powder, soluble in water, freely soluble in methanol and slightly soluble in ethanol. It is a quaternary ammonium compound and thus exists in an ionized state in aqueous solutions. It is insoluble in isopropyl alcohol, chloroform, methylene chloride and benzene.
Ipratropium Bromide Inhalation Solution is administered by oral inhalation with the aid of a nebulizer. Each mL contains ipratropium bromide, USP 0.02% (anhydrous basis) in a sterile, preservative-free, isotonic saline solution, pH adjusted to 3.4 (3 to 4) with hydrochloric acid.


Ipratropium Bromide Inhalation Solution is an anticholinergic (parasympatholytic) agent that, based on animal studies, appears to inhibit vagally-mediated reflexes by antagonizing the action of acetylcholine, the transmitter agent released from the vagus nerve.
Anticholinergics prevent the increases in intracellular concentration of cyclic guanosine monophosphate (cyclic GMP) which are caused by interaction of acetylcholine with the muscarinic receptor on bronchial smooth muscle.
The bronchodilation following inhalation of Ipratropium Bromide Inhalation Solution is primarily a local, site-specific effect, not a systemic one. Much of an administered dose is swallowed but not absorbed as shown by fecal excretion studies. Following nebulization of a 2 mg dose, a mean 7% of the dose was absorbed into the systemic circulation either from the surface of the lung or from the gastrointestinal tract. The half-life of elimination is about 1.6 hours after intravenous administration. Ipratropium bromide is minimally (0 to 9% in vitro) bound to plasma albumin and α1 -acid glycoproteins. It is partially metabolized. Autoradiographic studies in rats have shown that ipratropium bromide does not penetrate the blood-brain barrier. Ipratropium Bromide Inhalation Solution has not been studied in patients with hepatic or renal insufficiency. It should be used with caution in those patient populations.
In controlled twelve-week studies in patients with bronchospasm associated with chronic obstructive pulmonary disease (chronic bronchitis and emphysema) significant improvements in pulmonary function (FEV1 increases of 15% or more) occurred within 15 to 30 minutes, reached a peak in 1 to 2 hours and persisted for periods of 4 to 5 hours in the majority of patients, with about 25 to 38% of the patients demonstrating increases of 15% or more for at least 7 to 8 hours. Continued effectiveness of ipratropium bromide was demonstrated throughout the 12-week period. In addition, significant increases in forced vital capacity (FVC) have been demonstrated. However, ipratropium bromide did not consistently produce significant improvement in subjective symptom scores nor in quality of life scores over the 12-week duration of study.
Additional controlled 12-week studies were conducted to evaluate the safety and effectiveness of Ipratropium Bromide Inhalation Solution administered concomitantly with the beta adrenergic bronchodilator solutions metaproterenol and albuterol compared with the administration of each of the beta agonists alone. Combined therapy produced significant additional improvement in FEV1 and FVC. On combined therapy, the median duration of 15% improvement in FEV1 was 5 to 7 hours, compared with 3 to 4 hours in patients receiving a beta agonist alone.


Ipratropium Bromide Inhalation Solution administered either alone or with other bronchodilators, especially beta adrenergics, is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.


Ipratropium bromide is contraindicated in known or suspected cases of hypersensitivity to ipratropium bromide, or to atropine and its derivatives.


The use of Ipratropium Bromide Inhalation Solution as a single agent for the relief of bronchospasm in acute COPD exacerbation has not been adequately studied. Drugs with faster onset of action may be preferable as initial therapy in this situation. Combination of Ipratropium Bromide Inhalation Solution and beta agonists has not been shown to be more effective than either drug alone in reversing the bronchospasm associated with acute COPD exacerbation.
Immediate hypersensitivity reactions may occur after administration of ipratropium bromide, as demonstrated by rare cases of urticaria, angioedema, rash, bronchospasm and oropharyngeal edema.



Ipratropium bromide should be used with caution in patients with narrow angle glaucoma, prostatic hypertrophy or bladder neck obstruction.

Information for Patients

Patients should be advised that mydriasis, temporary blurring of vision, precipitation or worsening of narrow-angle glaucoma or eye pain may result if the solution comes into direct contact with the eyes. Use of a nebulizer with mouthpiece rather than face mask may be preferable, to reduce the likelihood of the nebulizer solution reaching the eyes. Patients should be advised that Ipratropium Bromide Inhalation Solution can be mixed in the nebulizer with albuterol or metaproterenol if used within one hour. Drug stability and safety of Ipratropium Bromide Inhalation Solution when mixed with other drugs in a nebulizer have not been established. Patients should be reminded that Ipratropium Bromide Inhalation Solution should be used consistently as prescribed throughout the course of therapy.

Drug Interactions

Ipratropium bromide has been shown to be a safe and effective bronchodilator when used in conjunction with beta adrenergic bronchodilators. Ipratropium bromide has also been used with other pulmonary medications, including methylxanthines and corticosteroids, without adverse drug interactions.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Two-year oral carcinogenicity studies in rats and mice have revealed no carcinogenic potential at dietary doses up to 6 mg/kg/day of ipratropium bromide.

Results of various mutagenicity studies (Ames test, mouse dominal lethal test, mouse micronucleus test and chromosome aberration of bone marrow in Chinese hamsters) were negative.
Fertility of male or female rats at oral doses up to 50 mg/kg/day was unaffected by ipratropium bromide administration. At doses above 90 mg/kg, increased resorption and decreased conception rates were observed.



Pregnancy Category B
Oral reproduction studies performed in mice, rats and rabbits at doses of 10, 100, and 125 mg/kg respectively and inhalation reproduction studies in rats and rabbits at doses of 1.5 and 1.8 mg/kg (or approximately 38 and 45 times the recommended human daily dose) respectively, have demonstrated no evidence of teratogenic effects as a result of ipratropium bromide. However, no adequate or well controlled studies have been conducted in pregnant women. Because animal reproduction studies are not always predictive of human response, ipratropium bromide should be used during pregnancy only if clearly needed.

Nursing Mothers

It is not known whether ipratropium bromide is excreted in human milk. Although lipid-insoluble quaternary bases pass into breast milk, it is unlikely that ipratropium bromide would reach the infant to a significant extent, especially when taken by inhalation since ipratropium bromide is not well absorbed systemically after inhalation or oral administration. However, because many drugs are excreted in human milk, caution should be exercised when ipratropium bromide is administered to a nursing woman.

Pediatric Use

Safety and effectiveness in pediatric patients below the age of 12 have not been established.


Adverse reaction information concerning Ipratropium Bromide Inhalation Solution is derived from 12-week active-controlled clinical trials. Additional information is derived from foreign post-marketing experience and the published literature.

All adverse events, regardless of drug relationship, reported by three percent or more patients in the 12-week controlled clinical trials appear in the table.

Additional adverse reactions reported in less than three percent of the patients treated with ipratropium bromide include tachycardia, palpitations, eye pain, urinary retention, urinary tract infection and urticaria. Cases of precipitation or worsening of narrow-angle glaucoma, mydriasis, and acute eye pain have been reported.

Lower respiratory adverse reactions (bronchitis, dyspnea and bronchospasm) were the most common events leading to discontinuation of ipratropium bromide therapy in the 12-week trials. Headache, mouth dryness and aggravation of COPD symptoms are more common when the total daily dose of ipratropium bromide equals or exceeds 2,000 mcg.

Allergic-type reactions such as skin rash, angioedema of tongue, lips and face, urticaria, laryngospasm and anaphylactic reaction have been reported. Many of the patients had a history of allergies to other drugs and/or foods.

All Adverse Events, From a Double-blind, Parallel, 12-week Study of Patients with COPD*
*All adverse events, regardless of drug relationship, reported by three percent or more patients in the 12-week controlled clinical trials
Ipratropium Bromide (500 mcg t.i.d.) n = 219 Metaproterenol (15 mg t.i.d.) n = 212 Ipratropium Bromide/ Metaproterenol (500 mcg t.i.d./15 mg t.i.d.) n = 108 Albuterol (2.5 mg t.i.d.) n = 205 Ipratropium Bromide/Albuterol (500 mcg t.i.d./2.5 mg t.i.d.) n = 100
Body as a Whole-General Disorders
Headache 6.4 5.2 6.5 6.3 9.0
Pain 4.1 3.3 0.9 2.9 5.0
Influenza-like Symptoms 3.7 4.7 6.5 0.5 1.0
Back Pain 3.2 1.9 1.9 2.4 0.0
Chest Pain 3.2 4.2 5.6 2.0 1.0
Cardiovascular Disorders
Hypertension/hypertension Aggravated 0.9 1.9 0.9 1.5 4.0
Central & Peripheral Nervous System
Dizziness 2.3 3.3 1.9 3.9 4.0
Insomnia 0.9 0.5 4.6 1.0 1.0
Tremor 0.9 7.1 8.3 1.0 0.0
Nervousness 0.5 4.7 6.5 1.0 1.0
Gastrointestinal System Disorders
Mouth Dryness 3.2 0.0 1.9 2.0 3.0
Nausea 4.1 3.8 1.9 2.9 2.0
Constipation 0.9 0.0 3.7 1.0 1.0
Musculo-skeletal System Disorders
Arthritis 0.9 1.4 0.9 0.5 3.0
Respiratory System Disorders (Lower)
Coughing 4.6 8.0 6.5 5.4 6.0
Dyspnea 9.6 13.2 16.7 12.7 9.0
Bronchitis 14.6 24.5 15.7 16.6 20.0
Bronchospasm 2.3 2.8 4.6 5.4 5.0
Sputum Increased 1.4 1.4 4.6 3.4 0.0
Respiratory Disorder 0.0 6.1 6.5 2.0 4.0
Respiratory System Disorders (Upper)
Upper Respiratory Tract Infection 13.2 11.3 9.3 12.2 16.0
Pharyngitis 3.7 4.2 5.6 2.9 4.0
Rhinitis 2.3 4.2 1.9 2.4 0.0
Sinusitis 2.3 2.8 0.9 5.4 4.0
Page 1 of 3 1 2 3

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2021. All Rights Reserved.